Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702141 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02702141 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 44 participants.
The verdict
NCT02702141, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The study will examine the safety profile of SGN-CD19B administered as a single agent. The main purpose of the study is to estimate the highest dose that does not cause unacceptable side effects of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) subtypes of diffuse large B-cell lymphoma (DLBCL) and Grade 3 follicular lymphoma (FL3). Additionally, the pharmacokinetic profile and antitumor activity of SGN-CD19B will be assessed.
Interventions
- DRUG SGN-CD19B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702141
The ClinicalTrials.gov registry entry for NCT02702141 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD19B is the first listed.
NCT02702141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702141 about?
NCT02702141 is a clinical study titled "A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma". The study will examine the safety profile of SGN-CD19B administered as a single agent. The main purpose of the study is to estimate the highest dose that does not cause unacceptable side effects of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) subtype...
What is the current status of trial NCT02702141?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-02. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02702141?
The interventions under investigation include: SGN-CD19B (DRUG).
Who is sponsoring clinical trial NCT02702141?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.